Adam Schayowitz Sells 13,832 Zymeworks Shares at $25.85 – Transaction Totals $357,557

On October 13, 2026, Adam Schayowitz, EVP and Head of R&D at Zymeworks Inc. (ticker ZYME), sold 13,832 shares at $25.85 per share, totaling $357,557, as per the mandatory SEC Form 4 filing.

Who is Adam Schayowitz and What is His Real Role at Zymeworks?

Adam Schayowitz holds the position of Executive Vice President (EVP) and Head of Research and Development (R&D) at Zymeworks, a biopharmaceutical company specializing in therapeutic protein development. As EVP, he is part of the executive team and involved in strategic decisions, including product pipelines, scientific collaborations, and research investments. His R&D role grants him direct access to clinical data, preclinical trial results, and new therapy launch plans, information not publicly available and potentially influencing market perceptions of the company's future value.

The EVP R&D position also entails overseeing research budgets, managing scientific teams, and coordinating with health authorities. This responsibility provides Schayowitz with a deep understanding of the risks and opportunities associated with ongoing projects and the ability to anticipate potential clinical delays or successes. Consequently, transactions by such executives are closely monitored by analysts, as they may reflect his internal assessment of the company's trajectory.

Transaction Details: 13,832 Shares at $25.85 Each

The SEC Form 4 indicates the transaction occurred on October 13, 2026. Schayowitz sold 13,832 Zymeworks shares, each sold at $25.85. The total value was calculated by multiplying the number of shares by the per-share price, resulting in $357,557. It's important to distinguish between the per-share price ($25.85) and the total value ($357,557), two distinct figures presented in the filing. No additional details, such as purchase options or short sales, are mentioned in the form.

Why Insiders Sell Their Shares – Possible Reasons

Share sales by executives can be motivated by various factors that don't necessarily reflect a negative view of the company. A common reason is portfolio diversification: executives often hold significant portions of their wealth in employer shares and may seek to reduce this risk by selling some of their holdings. Tax planning is also a frequent motivator; selling shares can allow for capital gains realization during a tax year with more favorable rates.

Personal liquidity needs, such as financing real estate purchases, educational expenses, or other private commitments, may justify a sale. Additionally, executives might take advantage of prices they view as attractive relative to their internal expectations, even if the market perceives the transaction as bearish. It's also important to note that regulations require declaring all transactions, even those resulting from prearranged plans (10-b or 10-b5-1), which allow scheduled sales independent of insider information.

How Individual Investors Track Form 4 Filings

Form 4 filings are made public on the Securities and Exchange Commission (SEC) website via the EDGAR platform. Individual investors can access these documents for free by searching for Zymeworks' ticker (ZYME) or the insider's name on the SEC EDGAR site. Many financial services aggregate this data and offer real-time alerts, such as WhaleWisdom, OpenInsider, or Bloomberg Terminal, enabling quick tracking of insider sales or purchases.

However, it's crucial to recognize the limitations of Form 4 information. The filing does not specify the exact motivations behind the transaction or the personal context of the insider. Additionally, sales may be prearranged and not reflect an immediate change in stock price direction. Investors should combine Form 4 analysis with other fundamental indicators, such as Zymeworks' financial results, clinical pipelines, and sector prospects, before making investment decisions.

In summary, the filing of a sale by Adam Schayowitz, EVP and Head of R&D at Zymeworks, involving 13,832 shares, represents a notable transaction that should be interpreted with caution. The transparency required by Form 4 provides investors with insight into executive activity, but the underlying reasons for the sale remain numerous and do not allow definitive conclusions about the stock's future direction.